Navigation Links
Vasogen Provides Update on ACCLAIM II Program
Date:3/3/2008

al clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2007, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... Now it's easy to make your RNA free of genomic DNA , ... , & Removal Reagents contain RNase-free DNase, ... to ensure safe, complete removal of , ... DNase Removal Reagent which, after digestion, eliminates DNase in , ...
... , ... RT-PCR and microarray gene expression analysis , ... no grinding or polytron required , ... tissue lysates , Faster and easier ...
... Low transfection efficiency and low cell , ... causes of unsuccessful gene , ... choosing the right transfection agent and transfection , ... in many cell types. Once a protocol is optimized ...
Cached Biology Technology:DNA-free A NEW Method to Remove DNA 2DNA-free A NEW Method to Remove DNA 3DNA-free A NEW Method to Remove DNA 4DNA-free A NEW Method to Remove DNA 5DNA-free A NEW Method to Remove DNA 6DNA-free A NEW Method to Remove DNA 7DNA-free A NEW Method to Remove DNA 8Hands-free Tissue Disruption No Homogenization Needed 2Hands-free Tissue Disruption No Homogenization Needed 3Hands-free Tissue Disruption No Homogenization Needed 4Hands-free Tissue Disruption No Homogenization Needed 5Hands-free Tissue Disruption No Homogenization Needed 6Hands-free Tissue Disruption No Homogenization Needed 7Optimizing siRNA Transfection for RNAi 2Optimizing siRNA Transfection for RNAi 3Optimizing siRNA Transfection for RNAi 4Optimizing siRNA Transfection for RNAi 5Optimizing siRNA Transfection for RNAi 6Optimizing siRNA Transfection for RNAi 7Optimizing siRNA Transfection for RNAi 8Optimizing siRNA Transfection for RNAi 9Optimizing siRNA Transfection for RNAi 10Optimizing siRNA Transfection for RNAi 11
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... There,s currently no reliable tool to help prosthetic developers ... medical personnel when bed-ridden patients need to be moved to ... now on the way. Prof. Amit Gefen of Tel Aviv ... a new device he calls the Soft Tissue Stress Monitor, ...
... and WEST PALM BEACH, Fla. , ... of authentication and endpoint protection solutions and ScriptRx, a ... Discharge Systems for Emergency Rooms and Urgent Care Centers, ... DigitalPersona into the ScriptRx System. Designed for these busy ...
... variant of a receptor in the brain,s reward circuitry ... dopamine is released in the brain following alcohol intake, ... National Institute on Alcohol Abuse and Alcoholism (NIAAA), part ... involved in transmitting the euphoria and other positive subjective ...
Cached Biology News:Finding the soft spot 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 3ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 4Receptor variant influences dopamine response to alcohol 2
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
Yeast tRNA 50 l...
...
... Low volume pipetting is increasingly ... volumes in DNA sequencing and other ... with performance and precision unparalleled in ... documented confirmation of all aspirated,and dispensed ...
Biology Products: